CSS
MBRX icon

Cubist Systematic Strategies’s Moleculin Biotech MBRX Stock Holding History

Cubist Systematic Strategies’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-71
Closed -$109K – 3017
2021
Q1 		$109K Buy
+71
New +$130K ﹤0.01% 2626

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Cubist Systematic Strategies's MBRX Position: Q2 2021 in Review

Cubist Systematic Strategies sold out of Moleculin Biotech (MBRX) in Q2 2021, closing a stake of 71 shares — an estimated $109K sold.

Cubist Systematic Strategies first reported a position in MBRX in Q1 2021 and held it in 1 quarter. The position peaked at $109K in Q1 2021. 28 funds tracked by Wall St. Rank hold MBRX as of Q2 2021.

  • Cubist Systematic Strategies reported no remaining Moleculin Biotech position as of Q2 2021 after selling out during the quarter.
  • Cubist Systematic Strategies sold 71 Moleculin Biotech shares in Q2 2021, an estimated $109K.
  • Cubist Systematic Strategies first reported a position in Moleculin Biotech in Q1 2021 and held it in 1 quarter.
  • Cubist Systematic Strategies's Moleculin Biotech position peaked at $109K in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2021.

Based on Cubist Systematic Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.